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Abstract
Perampanel is an aryl substituted 2-pyridone AMPA receptor antagonist that was recently approved as a treatment for
epilepsy. The drug potently inhibits AMPA receptor responses but the mode of block has not been characterized. Here the
action of perampanel on AMPA receptors was investigated by whole-cell voltage-clamp recording in cultured rat
hippocampal neurons. Perampanel caused a slow (t,1 s at 3 mM), concentration-dependent inhibition of AMPA receptor
currents evoked by AMPA and kainate. The rates of block and unblock of AMPA receptor currents were 1.56105 M21 s21
and 0.58 s21, respectively. Perampanel did not affect NMDA receptor currents. The extent of block of non-desensitizing
kainate-evoked currents (IC50, 0.56 mM) was similar at all kainate concentrations (3–100 mM), demonstrating a
noncompetitive blocking action. Parampanel did not alter the trajectory of AMPA evoked currents indicating that it does
not influence AMPA receptor desensitization. Perampanel is a selective negative allosteric AMPA receptor antagonist of
high-affinity and slow blocking kinetics.
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Introduction
AMPA receptors are members of the ionotropic glutamate
receptor family of ligand-gated ion channels [1]. At excitatory
synapses throughout the central nervous system, AMPA receptors
play a key role as transducers of synaptically released glutamate
into fast postsynaptic neuron depolarization. AMPA receptors also
are critical to epileptic synchronization and the spread of epileptic
seizures, so that pharmacological inhibitors of AMPA receptors
have utility in the treatment of epilepsy [2,3]. The first type of
selective AMPA receptor antagonist to be described were
competitive antagonists, which bind to the recognition site for
glutamate in the ligand binding domain (LBD), stabilizing a closed
form of the channel by preventing closure of the clamshell-like
LBD [4,5]. Shortly after the identification of competitive AMPA
receptor antagonists, a second type of selective AMPA receptor
antagonist was described that acts in a noncompetitive fashion
with respect to agonists. These negative allosteric modulators
include 2,3-benzodiazepines such as GYKI 52466 [6–9] and the
related quinazolinone CP-465,022 [10], which bind within peptide
segments of AMPA receptor subunits that link the LBD to the
transmembrane spanning region [11]. Antagonist occupancy at
this site inhibits the transduction of agonist binding into channel
gating.
Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyri-
din-3-yl)benzonitrile] is a structurally novel AMPA receptor
antagonist that is effective in the treatment of partial and
secondarily generalized seizures in humans [12,13]. 2,4-Diphe-
nyl-4H-[1,3,4]oxadiazin-5-one, the template molecule on which
perampanel is based, was discovered by high throughput screening
using a rat cortical neuron AMPA-induced cell death assay [14].
Systematic optimization of this template led to the discovery of
perampanel, which exhibited high potency as an inhibitor of
AMPA-induced Ca2+ influx in cultured rat cortical neurons (IC50,
0.093 mM) [15]. Studies to date have indicated that perampanel is
highly selective. Even a high concentration (30 mM) only
minimally inhibits NMDA responses and there is no evidence
that perampanel interacts with other ion channel targets. In
radioligand binding studies, [3H]perampanel binding to rat
forebrain membranes was displaced by CP-465,022 and GKYI
52466, indicating that all three agents interact at a common (or
allosterically-coupled) site on AMPA receptors. Perampanel has
also shown selectivity for AMPA receptor mediated synaptic
responses in recordings of field excitatory postsynaptic potentials in
the CA1 area in rat hippocampal slices [16]. In these recordings,
perampanel inhibited the AMPA receptor component of the field
response (IC50, 0.23 mM), without affecting the NMDA or kainate
receptor components.
While the information available to date is consistent with
perampanel acting as a high potency AMPA receptor antagonist,
complex effects on the concentration-response curve for AMPA in
the Ca2+ flux assay have precluded a precise definition of the mode
of inhibition [17]. Therefore, the objective in the present study was
to characterize the blocking mechanism using whole cell patch
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clamp techniques. The experimental paradigm also allowed us to
define the blocking kinetics. Our results confirm that perampanel
inhibits AMPA receptors in a noncompetitive fashion and
demonstrate that the onset and recovery of block occurs slowly
but is fully reversible.
Materials and Methods
Neuronal cultures
All experimental protocols in this work were reviewed and
approved by the Institutional Animal Care and Use Committee of
the University of California, Davis in compliance with the Animal
Welfare Act and in accordance with Public Health Service Policy
on the Humane Care and Use of Laboratory Animals.
Primary hippocampal neuronal cultures were prepared as
previously described [18]. In brief, timed pregnant rats Sprague-
Dawley rats (Charles River Laboratories International, Wilming-
ton, MA, USA) were anesthetized with isoflurane. E18 embryos
were obtained and the hippocampi were dissected and treated in
Hank’s balanced salt solution (HBSS; Invitrogen, Carlsbad, CA,
USA) with trypsin (0.03%, Sigma-Aldrich, St. Louis, MO) for
20 min at 37uC. After inactivation of trypsin with neuronal
medium (Neurobasal medium; Invitrogen, Life Technologies,
Grand Island, NY, USA) supplemented with NS21, 0.5 mM
glutamine, 10 mM HEPES) plus 5% horse serum (HS; Invitro-
gen), the tissue was washed twice with HBSS, and triturated with a
fire-polished Pasteur pipette. After non-dissociated pieces of tissue
settled, cells in the supernatant were collected by centrifugation
(1100 rpm at 2006g for 3.5 min), re-suspended in neuronal
medium plus 5% horse serum, counted, and plated on coverslips
(Warner Instruments, Hamden, CT, USA) coated with 0.1% (w/v)
poly-L-lysine (Peptides International, Louisville, KY, USA). The
cell density was 36104 cm22 in plating medium. After 4 h, the
medium was replaced with serum-free neuronal medium. Cells
were grown in a humidified environment of 95% air/5% CO2 at
37uC. One third of medium was changed after 5 days in vitro
(DIV) and weekly thereafter.
Voltage-clamp recording
Whole-cell voltage clamp experiments were performed 7–25
days after plating. For AMPA- and kainate-mediated currents,
recordings were made in a bath solution containing 135 mM
NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES,
1 mM tetrodotoxin (TTX), 10 mM bicuculline, 1 mM strychnine,
and 500 nM MK-801. The pipette solution contained 145 CsCl,
0.1 mM CaCl2, 2 mMMgCl2, 1 mM EGTA, and 5 mM HEPES.
For NMDA-mediated currents, recordings were made in a bath
solution containing 135 mM NaCl, 5 mM KCl, 0.2 mM CaCl2,
10 mM HEPES, 1 mM TTX, 10 mM bicuculline, 1 mM strych-
nine, 10 mM NBQX, 3 mM glycine. The pipette solution
contained 145 CsCl, 0.1 mM CaCl2, 1 mM EGTA, and 5 mM
HEPES.
Recordings were made with an Axopatch 200B patch-clamp
amplifier (Axon Instruments, Foster City, CA, USA). Whole-cell
currents were filtered at 2 kHz and digitized at 10 kHz. All
neurons were voltage-clamped at 260 mV. The following drugs
dissolved in bath solution were applied using a fast perfusion
system (VC3-8XP, ALA Scientific Instrument, NY, USA): kainate
(3, 10, 100 mM), AMPA (10, 30, 100 mM), NMDA (10, 100 mM),
and perampanel (0.01–30 mM). All were from Sigma-Aldrich
except perampanel, which was from Eisai Inc. Solution reservoirs
contained the drugs separately or the combination of an agonist
(kainate, AMPA or NMDA) plus perampanel. Each solution
reservoir was connected to a pinch valve of the 8-channel VC3-
8XP perfusion system, which fed solution to an 8-to-1 mini-
manifold (MP-8, Warner Instruments, Hamden, CT) that has a
dead-volume of 3.5 ml when switching between solutions. Only
one perfusion line was open at a time. The opening speed was 15–
20 ms. The command for switching among perfusion lines was
generated by the pClamp software and delivered to the control
box of the perfusion system via a TTL connection.
Statistical analysis
Data are expressed as means 6 S.E.M. Differences were
considered significant at p,0.05. The statistical analyses were
performed with SigmaStat software (SPSS Inc., Chicago, IL,
USA), except that IC50 values were compared using SAS software
(SAS Institute, Cary NC, USA) as described in the caption to
Table 1.
Results
Perampanel inhibition of AMPA responses
Rapid perfusion of AMPA onto cultured hippocampal neurons
at a holding potential of –60 mV elicited an inward current
response that decayed rapidly to a steady-state level (Fig. 1A).
Preapplication of perampanel for 5 s followed by coapplication of
perampanel together with AMPA resulted in a reduction in the
Table 1. IC50 Values for Perampanel Inhibition of AMPA- and Kainate-Evoked Currents.
Agonist Concentration AMPA/kainate (mM) AMPA Response Kainate Response IC50 (mM)
IC50, Peak Current, (mM) IC50, Late Current, (mM)
10/3 0.4 0.4 0.58
30/10 0.8 0.9 0.51
100/100 0.9 1.2 0.58
10 mM vs. 30 mM p=0.0075 p,0.0001 3 mM vs. 10 mM NS
10 mM vs. 100 mM p=0.0003 p,0.0001 3 mM vs. 100 mM NS
30 mM vs. 100 mM NS NS 10 mM vs. 100 mM NS
IC50 values are the concentration of perampanel estimated to inhibit the current response by one-half, as determined by logistic fits to the mean percent of control
values as presented in Fig. 1D and E, and Fig. 2B. To assess statistical significance of differences between the IC50 values, the perampanel concentration-response
relationship was linearized. The concentration was log transformed and the current response was transformed as logit Y = ln [(Y+e)/(Ymax – Y+e)]. Analysis of covariance
models were used to estimate IC50 values. Differences among the IC50 values were tested for significance by comparing the response lines against a common response
line, estimated without regard to the concentration. A Tukey-Cramer adjustment was used on those post hoc comparisons. NS, not significant.
doi:10.1371/journal.pone.0108021.t001
Perampanel Block of AMPA Receptors
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amplitude of the peak and late AMPA response, where the late
response is taken as the current amplitude at the end of the 5 s
AMPA perfusion. The peak and late response amplitude were
reduced to a similar extent. This is illustrated in Fig. 1B for
recordings in the presence of 1 mM perampanel (which produced
near half-maximal inhibition) where the mean 6 S.E.M. peak to
late ratio was not statistically different from control irrespective of
the AMPA concentration. Similarly, as illustrated in Fig. 1C,
1 mM perampanel did not alter the rise time constant or decay
time constant at any of the AMPA concentrations. The percent of
control peak and late current amplitude values for various
perampanel concentrations are plotted in Figs. 1D and E,
respectively, for currents evoked by 10, 30 and 100 mM AMPA.
Perampanel causes a concentration-dependent inhibition of the
peak and late current responses. IC50 (half-maximum inhibition)
values are 0.4, 0.8, and 0.9 mM for peak AMPA-induced currents
for AMPA concentrations of 3, 30 and 100 mM, respectively. The
corresponding IC50 values for late currents are 0.4, 0.9, and
1.2 mM. As shown in Table 1, there is a statistically significant
difference in the IC50 values obtained with 10 mM AMPA and
Figure 1. Perampanel inhibition of AMPA-evoked currents in cultured hippocampal neurons. (A) Sample currents evoked by 100 mM
AMPA in 4 neurons in the absence (left panels) and presence (right panels) of perampanel at the concentrations indicated demonstrating a
concentration-dependent reduction in current. (B) Perampanel (1 mM) did not alter the mean values of the ratio of the peak to the late amplitude of
currents evoked by 10, 30 and 100 mM AMPA in 7, 8 and 7 neurons, respectively, and (C) did not affect the mean rise time constant values or mean
decay time constant values of the currents. Peak (D) and late (E) current values evoked by various AMPA concentrations expressed as percent of
control prior to perampanel. Curves represent logistic fits to the data for each AMPA concentration. Peak current is the maximum current level; late
current is the current during the last 100 ms of the perfusion. Data points in D and E represent mean 6 S.E.M. of values from 3 to 9 neurons. Control
values for peak/late ratio: 10 mM AMPA: 1.560.1; 30 mM AMPA: 1.760.1; 100 mM AMPA: 2.760.3. Control values for decay time constant (ms): 10 mM
AMPA: 141613; 30 mM AMPA: 9367; 100 mM AMPA: 5062. Control values for rise time (ms): 10 mM AMPA: 5162; 30 mM AMPA: 4563; 100 mM AMPA:
3261.
doi:10.1371/journal.pone.0108021.g001
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those obtained with 30 and 100 mM AMPA. The slight shift in
IC50 indicates an interaction between perampanel and AMPA
binding (see Discussion).
Perampanel inhibition of kainate responses
Rapid perfusion of 100 mM kainate onto cultured hippocampal
neurons at a holding potential of –60 mV elicited a steady inward
current response (Fig. 2A). Preapplication of perampanel for 5 s
followed by coapplication of perampanel together with kainate
resulted in a concentration-dependent reduction in the amplitude
of the kainate responses without a consistent alteration in the
shape of the responses. The percent of control current amplitude
values at various perampanel concentrations are plotted in Fig. 2B
for three kainate concentrations (3, 10, and 100 mM). The IC50
values are 0.58, 0.51, and 0.58 mM for kainate concentration 3,
10, and 100 mM, respectively. As shown in Table 1, the IC50
values are not significantly different.
Kinetics of perampanel block
To assess the rate of perampanel block and unblock we initiated
and terminated perampanel fast perfusion in the presence of the
agonists kainate and AMPA as illustrated in Fig. 3. Fig. 3A shows
sample traces from an experiment with kainate in one neuron. Fast
perfusion of kainate 5 s after perampanel (3 mM) perfusion had
been initiated resulted in a reduction of the kainate-induced
current by ,73% (Fig. 3A2 versus Fig. 3A1), consistent with the
results shown in Fig. 2. Concurrent application of kainate and
perampanel (Fig. 3A3) resulted in a decaying current response
suggesting the slow development of block over the 5 s combined
perfusion. The peak initial current amplitude was modestly
reduced from the initial control current amplitude as demonstrat-
ed by the summary value (bar A3) in Fig. 3C1. However the
magnitude of the late current (bar A3 in Fig. 3C2) amplitude was
not different from the magnitude of the late current with
perampanel pretreatment (bar A2 in Fig. 3C2). These results
demonstrate that perampanel block develops more slowly than
channel activation but reaches a plateau that is similar to that
achieved with perampanel pretreatment. Similar conclusions can
be drawn from the paradigm of Fig. 3A4 where perampanel
perfusion is initiated 5 s after the onset of kainate perfusion. The
slow development of block (t=1.260.1 s) is clearly illustrated, as
is the slow recovery from block (t=3.361.5 s).
Similar results were obtained when AMPA was used as the
agonist, as illustrated in Fig. 3B. Fast perfusion of AMPA 5 s after
the onset of perampanel resulted in reduction in the peak and late
responses to a similar extent (,60%; Fig. 3B2). In contrast, when
perampanel and AMPA were applied simultaneously, the peak
response was reduced less (17%) than the late response (Fig. 3B3),
suggesting that perampanel block is slow to develop. As the extent
of late block is similar to the situation with pretreatment, full block
is established within 5 s of the recording (Fig. 3D2, compare bar
B3 with B2). The slow development of block is confirmed when
perampanel perfusion is begun following preexposure to AMPA
(Fig. 3B4); this exposure paradigm also demonstrates slow
recovery of block of AMPA-evoked current.
The rate constants for binding and unbinding of perampanel
were determined from experiments like those shown in Fig. 3B4
with perampanel concentrations of 1, 3 and 10 mM. Apparent rate
constants for the approach to equilibrium block (kapp) were
calculated as the reciprocal of the time constant values for the
onset of block, which are shown in Fig. 4A. As demonstrated by
the plot in Fig. 4B, kapp increases in a linear fashion with
increasing perampanel concentration. Assuming a simple one-to-
one binding reaction for block, kapp = k1[Perampanel]+k–1, where
k1 and k–1 are the binding and unbinding rate constants,
empirically determined from the best fit straight line to the data
as 1.5160.106105 M21 s21 and 0.5860.6 s21, respectively. The
mean off rate determined from the toff values in Fig. 4A is
0.68 s21, which is in good accordance with the value determined
assuming a unimolecular binding reaction (intercept of straight
line fit in Fig. 4B). The kinetically determined binding affinity
(KD= k–1/k1) is 3.9 mM.
Figure 2. Perampanel inhibition of kainate-evoked currents in
cultured hippocampal neurons. (A) Sample currents evoked by
100 mM kainate in 4 neurons in the absence (left panels) and presence
(right panels) of perampanel at the concentrations indicated. The
percent inhibition values (derived from the current amplitude in the
absence of perampanel and the corresponding current amplitude in the
presence of perampanel) are 20%, 41%, 55%, and 80% at concentra-
tions of 0.1, 0.3, 1, and 3 mM, respectively. (B) Current amplitude values
evoked by various kainate concentrations expressed as percent of
control prior to perampanel. Curves represent logistic fits to the data for
each kainate concentration. Data points represent mean 6 S.E.M. of
values from 3 to 6 neurons.
doi:10.1371/journal.pone.0108021.g002
Perampanel Block of AMPA Receptors
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Perampanel has no effect on NMDA responses
Rapid perfusion of 10 and 100 mM NMDA onto cultured
hippocampal neurons at a holding potential of 260 mV elicited
inward current responses that decayed modestly during the 5 s
perfusion (Fig. 5A). Preapplication of perampanel (30 mM) for 5 s
followed by coapplication of perampanel together with NMDA
failed to affect the mean amplitudes of the peak (Fig. 5B) or late
(Fig. 5C) NMDA-evoked current.
Discussion
The results of the present study demonstrate that perampanel is
a selective noncompetitive AMPA receptor antagonist. In neurons
cultured from E18 rat embryos, kainate predominantly activates
non-desensitizing or weakly-desensitizing AMPA receptor respons-
es [19–22]. In addition, however, in some neurons smaller, rapidly
desensitizing currents generated by kainate receptors are present.
These currents desensitize completely and the speed of desensi-
tization is so fast (t , 20 ms) that they do not contribute in a
meaningful way to the kainate currents observed in the slower
time-scale recordings of the present study. Therefore, for practical
purposes, the current responses generated by kainate can be
assumed to be mediated by AMPA receptors. Because AMPA
receptor currents activated by kainate do not desensitize or
desensitize very rapidly to only a limited extent, they are well
suited for studies on the mode and kinetics of block since
complications caused by desensitization are avoided. In the
present study, perampanel blocked kainate-evoked AMPA recep-
tor current to a similar extent irrespective of the kainate
concentration, confirming a noncompetitive (allosteric) blocking
mechanism. The blocking potency (IC50, 0.56 mM) was compa-
rable to that obtained in a previous study in brain slices [16]. The
Figure 3. Slow onset and recovery from perampanel block of kainate- and AMPA-evoked currents. (A) Currents evoked by 100 mM
kainate in the absence (A1) and with pre-application (A2), co-application (A2) and post-application (A3) of perampanel (3 mM) in the same neuron. (B)
Currents evoked by 100 mM AMPA in the absence (B1) and with pre-application (B2), co-application (B2) and post-application (A3) of perampanel
(3 mM) in a different neuron from (A). Open arrows indicate peak current levels in the case of AMPA-evoked currents and the current at 100 ms after
onset of agonist application in the case of kainate-evoked currents; closed arrows indicate late current levels (end of agonist application). Scale for
current is 300 pA in (A) and 500 pA in (B). (C) Mean 6 S.E.M. values of peak (C1) and late (C2) current levels as a percent of control (as in A1) with
perampanel pre-application (as in A2), co-application (as in A3) and post-application (as in A4) in 3–4 neurons (D) Mean 6 S.E.M. values of peak (D1)
and late (D2) current levels as a percent of control (as in B1) with perampanel pre-application (as in B2), co-application (as in B3) and post-application
(as in B4) in 4 neurons. *p,0.05 vs. A2 or B2.
doi:10.1371/journal.pone.0108021.g003
Perampanel Block of AMPA Receptors
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e108021
trajectory of kainate-evoked currents was not affected by
perampanel. In other words, there was comparable inhibition of
the initial current amplitude representing the extent to which
closed channels are blocked and the late current amplitude
representing the steady-state block of open channels. These
findings indicate that perampanel inhibits closed and open
channels to a similar extent. This conclusion can be made with
confidence inasmuch as perampanel block occurs on a time scale
that is much slower (Fig. 3A3) than agonist activation of the
channel (Fig. 3A1).
The potency of perampanel block of AMPA receptor responses
evoked by a low concentration of AMPA (10 mM) was comparable
to the block of kainate-evoked AMPA receptor responses.
However, the perampanel dose-inhibition curves were shifted
slightly to the right as the concentration of AMPA was increased.
Since perampanel block of kainate-evoked AMPA receptor
responses did not exhibit this shift, it is unlikely to be due to a
competitive blocking interaction. A more plausible explanation is
that binding of AMPA transmits a change in conformation to the
linker region where perampanel binds, reducing its affinity.
Kainate may not induce this effect because it is a partial agonist
[20,23]. Whereas AMPA causes ,20u of LBD closure which
results in strong AMPA receptor desensitization, kainate induces
only ,12u of LBD closure that fails to fully activate the receptor
and to desensitize it. AMPA therefore causes greater structural
movement than kainate, and the effect of AMPA could be
sufficient to influence the interaction of perampanel with its
recognition site. In contrast, kainate may not produce a large
enough conformational change to influence perampanel binding.
An alternative explanation is that the reduced blocking potency
relates to reduced affinity of perampanel for desensitized AMPA
receptor channels. With AMPA as agonist, due to the rapidity of
desensitization, a fraction of the channels even at the onset of
perfusion are in the desensitized state [24]. Moreover, the extent of
desensitization increases with increasing AMPA concentration
[24]. Thus, a reduced affinity of perampanel accompanying
desensitization would account for the shift. The apparent more
pronounced effect on late than peak current (compare Figs. 1E
and 1D) is compatible with this possibility. As is the case for 2,3-
benzodiazepine allosteric AMPA receptor inhibitors [6,24,25],
perampanel did not affect the rate or extent of AMPA receptor
desensitization.
A noteworthy observation in the present study is the slow rate at
which perampanel block develops and at which unblock from
activated receptors occurs. This is demonstrated in the experi-
ments of Fig. 3 where preexposure to perampanel results in fully
developed block but without preexposure block develops over the
course of ,3 s. The speed of block is slower than that obtained
with 2,3-benzodiazepines. For example, block by GYKI 52466 at
a concentration causing ,50% inhibition of steady AMPA
receptor current (30 mM) occurs in several hundred milliseconds
[6,11]. The slower development of block by perampanel is largely
due to the slower dissociation rate reflecting higher affinity binding
to AMPA receptors. Thus, the association rates for GYKI 52466
[6] and perampanel (this study) are nearly identical at
1.66105 M21 s21 and 1.56105 M21 s21, respectively. However,
the dissociation rate of GYKI 52466 (3.2 s21) is much faster than
that of perampanel (0.58 s21) so that the approach to equilibrium
representing the sum of the association and dissociation rates is
slower for perampanel.
In sum, the present results support the conclusion that
perampanel is a noncompetitive antagonist of AMPA receptor
responses that acts in a similar fashion to structurally dissimilar
2,3-benzodiazepine and quinazolinone noncompetitive antago-
nists. However, perampanel is substantially more potent and
exhibits correspondingly slower rates of onset and recovery from
block. At steady-state (as is the case during chronic treatment for
epilepsy), early and late AMPA receptor responses would be
blocked to a similar extent and the block would not be overcome
by high synaptic glutamate concentrations as are believed to occur
during seizure activity (although there might be a slight effect due
to the long distance interaction between binding to the linker and
the LBD discussed above). Interictal and ictal epileptiform
discharges are much more prolonged than normal synaptic
responses; block of late activity is therefore expected to be
beneficial in seizure therapy. In contrast, competitive antagonists
preferentially block the early component of AMPA receptors
Figure 4. Kinetics of peramapanel block of AMPA-evoked
currents. (A) Time constants for block and unblock of 100 mM AMPA-
evoked currents determined from the best single exponential fits to
current traces at the onset (tapp) and termination (toff) of application of
1, 3 and 10 mM perampanel. (B) Reciprocal mean tapp values ( = kapp)
plotted against perampanel concentration. The best-fit straight line to
the data is shown. The slope and the intercept values are
1.560.16105 M21 s21 and 0.5860.6 s21, respectively.
doi:10.1371/journal.pone.0108021.g004
Figure 5. Perampanel does not inhibit NMDA-evoked currents
in cultured hippocampal neurons. (A) Sample currents evoked by
10 and 100 mM NMDA in the absence (left panels) and presence (right
panels) of perampanel (30 mM). (B) Mean 6 S.E.M. peak amplitude of
currents evoked by 10 and 100 mM NMDA during control conditions
(bath perfusion) and in the presence of perampanel. (C) Mean 6 S.E.M.
late amplitude of currents evoked by 10 and 100 mM NMDA during
control conditions (bath perfusion) and in the presence of perampanel.
Each bar represents data from 6 neurons.
doi:10.1371/journal.pone.0108021.g005
Perampanel Block of AMPA Receptors
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e108021
current and are less potent inhibitors of late current (see ref. [24]).
Unlike the situation for noncompetitive antagonists, the blocking
action of competitive antagonists can be overcome by high
glutamate concentrations occurring during seizures. Theoretically,
therefore, noncompetitive antagonists such as perampanel could
have advantages over competitive antagonists in the treatment of
epilepsy. In order for competitive antagonists to produce
acceptable seizure protection, correspondingly higher doses might
be required that would affect normal ongoing synaptic excitation
leading to side effects. In fact, the available information indicates
that perampanel provides clinically useful seizure protection with
an acceptable side-effect profile.
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